# Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

> **NCT07247383** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 39 (estimated)

## Conditions studied

- Marginal Zone Lymphoma of Ocular Adnexal
- Marginal Zone Lymphoma(MZL)

## Interventions

- **DRUG:** Orelabrutinib (ICP-022)
- **RADIATION:** radiotherapy
- **DRUG:** Rituximab (R)

## Key facts

- **NCT ID:** NCT07247383
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-19
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247383, "Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07247383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*